Search
for
Sort by
Research
480-510 / 1000+ results
research Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
Baricitinib significantly regrows hair in severe alopecia areata patients.
research The Free Communications of the Eighth Clinical Congress (Virtual) of the Gulf Chapter of the American Association of Clinical Endocrinologists; November 5–7, 2020
I'm sorry, but I can't provide a summary without the content of the document.
research 53028 Semaglutide and Hair Loss: A Real-World Analysis
Semaglutide does not significantly increase the risk of hair loss.
research Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
Abrocitinib may help treat alopecia areata effectively with mild side effects.
research Topical Delivery of Tofacitinib in Dermatology: The Promise of a Novel Therapeutic Class Using Biodegradable Dendritic Polyglycerol Sulfates
A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
research The Triumph of JAK Inhibitors for the Treatment of Alopecia Areata
JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
research Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force “Dermatology for Cancer Patients” International Study
Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research Assessment of the Impact of Atmospheric Cold Plasma Application on Wound Healing in Streptozotocin-Induced Diabetic Rats
Plasma-activated water heals diabetic wounds better than other treatments.
research Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity
Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
research Elucidation of the Underlying Mechanism of Gujian Oral Liquid Acting on Osteoarthritis through Network Pharmacology, Molecular Docking, and Experiment
Gujian oral liquid reduces osteoarthritis symptoms by targeting inflammation.
research Metformin in dermatology: an overview
Metformin is effective for various skin disorders but may cause skin side effects.
research Review of Baricitinib in the Treatment of Alopecia Areata.
Baricitinib is a relatively safe and effective treatment for severe alopecia areata.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Successful Treatment of Canities Subita with Baricitinib
Baricitinib may effectively treat sudden hair whitening and regrowth in some cases.
research Alopecia areata treatment with baricitinib: different relapse phenotypes
Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.
research Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
Different oral anticoagulants cause various non-bleeding side effects, so careful monitoring is needed.
research Preclinical evaluation of the diabetic wound healing activity of phytoconstituents extracted from Ficus racemosa Linn. leaves
Ficus racemosa leaf extracts help heal diabetic wounds and lower blood sugar.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas
Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.
research Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata
Baricitinib helps regrow scalp, eyebrow, and eyelash hair in teens with severe alopecia areata.
research Combined drug triads for synergic neuroprotection in retinal degeneration
Using three different drugs together may better treat eye diseases like glaucoma and macular degeneration.
research Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
Baricitinib reduces inflammation and improves cell health in premature aging cells.
research ¿Novedad o prudencia? El delicado equilibrio en la actualización farmacológica
New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
research Cosmetovigilance studies to assess the safety of cosmetic therapy in hair segments and skin non-laser
Cosmetovigilance and clinical pharmacists can enhance safety in cosmetic treatments, especially for those with diabetes.
research Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours
The drug combination was safe and showed promise in treating advanced tumors.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.